GATC Health Corp. Congratulates Advisory Board Member Dr. Richard Schatz on National Inventors Hall of Fame Induction

IRVINE, CA – March 13, 2025 – GATC Health Corp., a leading tech-bio company leveraging artificial intelligence (AI) to transform drug discovery, proudly congratulates Dr. Richard Schatz on his induction into the National Inventors Hall of Fame. Dr. Schatz, a distinguished cardiologist and a valued member of GATC Health's advisory board, is being recognized for his invention of the Palmaz-Schatz Coronary Stent, a groundbreaking innovation that has transformed the treatment of coronary artery disease worldwide.

“We are incredibly proud of Dr. Schatz and his remarkable achievements,” said John Stroh, Chief Executive Officer of GATC Health. “His pioneering work with the Palmaz-Schatz stent has saved countless lives and significantly improved the quality of life for millions. As a member of our advisory board, Dr. Schatz brings invaluable expertise and insights to GATC Health, helping us to push the boundaries of healthcare innovation.”

Dr. Schatz's induction into the National Inventors Hall of Fame is a testament to his dedication, ingenuity, and unwavering commitment to advancing medical science. His contributions to the field of cardiology have had a profound impact on global healthcare, and GATC Health is honored to be associated with such an accomplished and visionary leader.

GATC Health has attracted luminaries from many industries to its advisory board. In addition to Dr. Schatz, the board includes Herbert Boyer, co-founder of Genentech, which sold to Roche for $46.8 billion, and who was credited with pioneering gene editing; Lin Yu, Ph.D., former Managing Director for Healthcare Investment Banking at Oppenheimer and BTIG; Tomas Philipson, Ph.D., former Acting Chairman of the Council of Economic Advisers in the White House and Senior Economic Advisor to FDA, and others.

About GATC Health

GATC Health Corp. is a technology company transforming drug discovery and development through its AI-driven platform and approach. The company’s validated and proprietary Multiomics Advanced Technology™ (MAT) simulates human biochemistry’s billions of interactions to rapidly create novel therapeutics, identify and confirm targets, accelerate development, and de-risk drug pipelines by predicting efficacy, safety, and off-target effects.

For more information, visit www.gatchealth.com.